The FDA approved Eli Lilly’s oral obesity pill Foundayo (orforglipron), formally extending the market’s shift to oral GLP-1 receptor agonists. Analysts and company messaging immediately set up a competitive comparison with Novo Nordisk’s oral Wegovy (where dosing differs, including administration requirements on an empty stomach). Novo’s response emphasized differences in expected performance, referencing an analysis from its Orion study rather than a head-to-head trial against Foundayo. With both products now cleared for weight management, marketing, labeling interpretation, and adherence-related tradeoffs are likely to drive uptake. The approval also marks a catalyst-rich moment for the obesity category, as second-generation oral programs face heightened scrutiny for both efficacy and real-world tolerability.